Arturo Loaiza-Bonilla MD, MSEd

Arturo Loaiza-Bonilla, MD, MSEd, discusses the significant advancements and ongoing efforts in integrating artificial intelligence into oncology.

Arturo Loaiza-Bonilla, MD, MSEd, explains the background and findings of the phase 3 DESTINY-Gastric04 trial.

Arturo Loaiza-Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.

Arturo Loaiza-Bonilla, MD, MSEd, discusses the phase 3 ATOMIC trial presented at the 2025 American Society of Clinical Oncology Annual Meeting.

Arturo Loaiza-Bonilla, MD, MSEd, discusses the potential of disitamab vedotin, toripalimab, and chemotherapy/trastuzumab in first-line treatment.

Arturo Loaiza-Bonilla, MD, MSEd, discusses findings from the MATTERHORN trial in patients with resectable gastric or gastroesophageal junction adenocarcinoma.

Clinical trials play a pivotal role in developing effective therapies, yet their integration is challenged by issues such as insufficient reimbursement structures, misaligned incentives, physician burnout, and a complex regulatory environment.

Coronavirus disease 2019 has disrupted oncologic care across the spectrum of cancer screening, diagnosis, and management.